Is size the next big thing in epidemiology?
暂无分享,去创建一个
[1] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[2] W A Ray,et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor‐associated angioedema , 1996, Clinical pharmacology and therapeutics.
[3] John W. Glasser,et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. , 1997, Pediatrics.
[4] R Platt,et al. Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on therapeutics , 2001, Pharmacoepidemiology and drug safety.
[5] Sarah M. Greene,et al. Building a research consortium of large health systems: the Cancer Research Network. , 2005, Journal of the National Cancer Institute. Monographs.
[6] J. Avorn,et al. A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.
[7] Xiaodong Lin,et al. Secure Regression on Distributed Databases , 2005 .
[8] Donald R. Miller,et al. Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors , 2008, Hypertension.
[9] Tracy A. Lieu,et al. The Cardiovascular Research Network: A New Paradigm for Cardiovascular Quality and Outcomes Research , 2008, Circulation. Cardiovascular quality and outcomes.
[10] Richard Platt,et al. Design of a National Distributed Health Data Network , 2009, Annals of Internal Medicine.
[11] J. Avorn,et al. High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data , 2009, Epidemiology.
[12] Bruce Fireman,et al. Influenza Vaccination and Mortality: Differentiating Vaccine Effects From Bias , 2009, American journal of epidemiology.
[13] W. Ray,et al. Use of disease risk scores in pharmacoepidemiologic studies , 2009, Statistical methods in medical research.
[14] Jeremy A Rassen,et al. Privacy-Maintaining Propensity Score-Based Pooling of Multiple Databases Applied to a Study of Biologics , 2010, Medical care.
[15] J. Overhage,et al. Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership , 2010, Annals of Internal Medicine.
[16] R. Platt,et al. Distributed Health Data Networks: A Practical and Preferred Approach to Multi-Institutional Evaluations of Comparative Effectiveness, Safety, and Quality of Care , 2010, Medical care.
[17] Steven J. Jacobsen,et al. The Vaccine Safety Datalink: A Model for Monitoring Immunization Safety , 2011, Pediatrics.
[18] R. Platt,et al. Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.
[19] M. Schuemie,et al. Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project , 2011, Pharmacoepidemiology and drug safety.
[20] R Platt,et al. Comparative‐Effectiveness Research in Distributed Health Data Networks , 2011, Clinical pharmacology and therapeutics.
[21] Sengwee Toh,et al. Confounding adjustment via a semi‐automated high‐dimensional propensity score algorithm: an application to electronic medical records , 2011, Pharmacoepidemiology and drug safety.
[22] Marsha A Raebel,et al. Design considerations, architecture, and use of the Mini‐Sentinel distributed data system , 2012, Pharmacoepidemiology and drug safety.
[23] R. Davis,et al. Health Maintenance Organizations/Health Plans , 2012 .
[24] Richard Platt,et al. The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction , 2012, Pharmacoepidemiology and drug safety.
[25] Adrian F Hernandez,et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. , 2012, Archives of internal medicine.
[26] Sebastian Schneeweiss,et al. Using high‐dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system , 2012, Pharmacoepidemiology and drug safety.
[27] David McManus,et al. Validation of acute myocardial infarction in the Food and Drug Administration's Mini‐Sentinel program , 2013, Pharmacoepidemiology and drug safety.